https://www.selleckchem.com/pr....oducts/penicillin-st
Migraine can negatively impact patient functioning and quality of life. Here, we report the effects of galcanezumab (GM, a humanized monoclonal antibody that binds to calcitonin gene-related peptide, on patient-reported outcome (PRO) measures in migraine. CGAJ was a Phase III, randomized, open-label study (12-month open-label and 4-month post-treatment follow-up) in patients with episodic or chronic migraine. Patients aged 18-65years with diagnosis of migraine (≥ 4 migraine headache days per month) as defined by Intern
Like
Comment
Share
